[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]

The Federal Joint Committee [Gemeinsamer Bundesausschuss] (G-BA)
Record ID 32018004239
English, German
Original Title: Arzneimittel-Richtlinie/Anlage XII: Tisagenlecleucel (Neues Anwendungsgebiet: Follikuläres Lymphom, vorbehandelte Patienten)
Authors' objectives: The Federal Joint Committee [Gemeinsamer Bundesausschuss (G-BA)] has had the legal task of carrying out an (additional) benefit assessment for all newly approved drugs with new active ingredients immediately after market entry (§ 35a SGB V). The result of this assessment is the basis for deciding how much the statutory health insurance pays for a new drug with a new active ingredient. The G-BA was commissioned to carry out the benefit assessment through the Pharmaceuticals Market Reorganisation Act [Gesetz zur Neuordnung des Arzneimittelmarktes (AMNOG)]. In the context of the early benefit assessment of medicinal products containing new active substances, the following rules apply to orphan drugs: According to the legal requirements (§ 35a SGB V), the additional medical benefit of these drugs is already considered to be proven by the approval. The G-BA determines the extent of the additional benefit for orphan drugs that do not exceed a turnover of 50 million Euros in the last twelve calendar months, on the basis of the approval and the studies justifying the approval.
Authors' results and conclusions: Tisagenlecleucel is approved for the treatment of people with relapsed or refractory follicular lymphoma after two or more systemic therapies. The benefit assessment of Tisagenlecleucel is based on the pivotal ELARA study, a one-arm, open-label, and multicentric Phase II trial to investigate the safety and efficacy. An indirect comparison was rejected because of methodological shortcomings and limited comparability of study populations between clinical and real-world populations. Therefore it is not possible to draw conclusions on mortality and morbidity endpoints due to the missing control group. Side effects were mainly collected between the day of infusion and three months after infusion. Nearly every UE of special interest occurred in the trial, especially the Cytokine Release Syndrom. The safety assessment is limited due to differences in reporting between treatment phases and the missing control group.
Project Status: Completed
Year Published: 2022
Requestor: The Federal Joint Committee [Gemeinsamer Bundesausschuss] (G-BA)
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Lymphoma, Follicular
  • Receptors, Chimeric Antigen
  • Immunotherapy, Adoptive
  • Antineoplastic Agents, Immunological
  • Receptors, Antigen, T-Cell
Organisation Name: The Federal Joint Committee
Contact Address: Gutenbergstr. 13, 10587 Berlin, Germany
Contact Name: Fachberatung Medizin [Department of Medical Consultancy]
Contact Email: Fachberatung-Medizin@g-ba.de
Copyright: https://www.g-ba.de/sys/impressum/
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.